Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program

Contributed by: Business Wire

Logo

Tags

Oncology

FDA

Health

Clinical Trials

Pharmaceutical

Biotechnology

FDA's IND Approval for Bladder Cancer Program

More Like This

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial

Prokarium Appoints Ibs Mahmood as Chief Executive Officer

Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells